Docket

39530

Amgen Inc., et al. v. Pfizer Canada ULC

(Federal Court) (Civil) (By Leave)

(Certain information not available to the public)

Judgments on applications for leave to appeal are rendered by the Court, but are not necessarily unanimous.

Proceedings
Date Proceeding Filed By
(if applicable)
2021-06-07 All materials on application for leave submitted to the Judges, for consideration by the Court
2021-03-01 Certificate (on limitations to public access), (Letter Form), 23B-Reply, (Printed version due on 2021-03-08) Amgen Inc.
2021-03-01 Applicant's reply to respondent's argument, (Letter Form), Completed on: 2021-05-14, (Printed version due on 2021-03-08) Amgen Inc.
2021-02-19 Certificate (on limitations to public access), (Letter Form), (Included in the certificate (on limitations to public access)), 23B, (Printed version due on 2021-02-26) Pfizer Canada ULC
2021-02-19 Certificate (on limitations to public access), (Letter Form), 23A, (Printed version due on 2021-02-26) Pfizer Canada ULC
2021-02-19 Notice of name, (Letter Form), (Printed version due on 2021-02-26) Pfizer Canada ULC
2021-02-19 Respondent's response on the application for leave to appeal, (Book Form), CONFIDENTIAL

Confidential paper material filed 2021-02-19
Confidential electronic material filed 2021-03-17
Redacted electronic material filed 2021-02-19, Completed on: 2021-05-14, (Printed version filed on 2021-02-19)
Pfizer Canada ULC
2021-01-22 Letter acknowledging receipt of a complete application for leave to appeal, FILE OPENED: 2021-01-22
2021-01-04 Certificate (on limitations to public access), Form 23B
Amended version (Rec'd 2021-01-08)
Amgen Inc.
2021-01-04 Certificate (on limitations to public access), Form 23A
Required clarification RE 23A (Rec'd amended 23 A 2021-01-08.)
Amgen Inc.
2021-01-04 Notice of name Amgen Inc.
2021-01-04 Application for leave to appeal, (Book Form), CONFIDENTIAL: FC reasons for judgment are Confidential and were filed separately.
Public reasons for judgment filed with the application.

Required clarification RE 23A (Rec'd amended 23A and 23B 2021-01-08.), Completed on: 2021-01-04
Amgen Inc.